Sólo en 1998, Glaxo-Wellcome declaró, por la única venta de AZT, ganancias de 4,43 billones $ US. Véase Bond, 1999, «Globalization, Pharmaceutical Pricing and South African Health Policy : Managing Confrontation with U.S. Firms and Politicians», International Journal of Health Policy, vol.29, no.4, p.764-792.